Bide Pharmatech Co

Bide Pharmatech Co Gross Margin

The Gross Margin of Bide Pharmatech Co (688073.SS) as of Oct 22, 2026 is 44.54 %. In the previous year, Gross Margin was 41.33 % — a change of 7.75% (higher).

Gross Margin

44.54 %

YoY

7.75%

Last updated:

Gross Margin of Bide Pharmatech Co is 2025 44.54 % . Gross Margin of Bide Pharmatech Co was 2024 41.33 % . It decreases by 7.75% higher compared to the previous year.

For Bide Pharmatech Co, the gross margin of 44.5% is down versus 49.5% a few years ago.

The Bide Pharmatech Co Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2019
55.76 CNY
Jan 1, 2020
54.38 CNY
Jan 1, 2021
49.46 CNY
Jan 1, 2022
44.38 CNY
Jan 1, 2023
40.00 CNY
Jan 1, 2024
41.33 CNY
Jan 1, 2025
44.54 CNY
The Bide Pharmatech Co Gross Margin history
YEARGross MarginYoY
44.54 %+7.75%
41.33 %+3.33%
40.00 %-9.87%
44.38 %-10.27%
49.46 %-9.04%
54.38 %-2.49%
55.76 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bide Pharmatech Co Stock analysis

What does Bide Pharmatech Co do? Bide Pharmatech Co., Ltd. generates revenue through the research, development, design, production, and sales of pharmaceutical molecular building blocks and scientific reagents. The company's primary products serve drug target discovery, seed compound screening, lead compound discovery, synthesis, and optimization processes. Key markets include Asia Pacific, India, Europe, and the United States, where the firm's offerings are utilized by pharmaceutical companies and research institutions. The business model relies on direct sales of its specialized chemical products to these industry segments. The firm's main focus is on developing molecular building blocks for drug development, with products specifically designed for early-stage pharmaceutical research. These building blocks are essential for creating and refining potential drug candidates. The company's operations span multiple global regions, targeting pharmaceutical manufacturers and academic research organizations that require high-quality chemical compounds for their development pipelines. Bide Pharmatech's revenue streams are derived from the sale of its proprietary molecular building blocks and reagents, which are integral to pharmaceutical R&D processes. The company serves clients in the pharmaceutical sector across Asia Pacific, India, Europe, and the United States, delivering products that support critical stages of drug discovery and development. Bide Pharmatech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bide Pharmatech Co stock

Gross Margin of Bide Pharmatech Co is 44.54 % in 2025.

Gross Margin of Bide Pharmatech Co changed from 41.33 % to 44.54 %, representing a 7.75% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Bide Pharmatech Co since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Bide Pharmatech Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Bide Pharmatech Co

All Key Metrics — Bide Pharmatech Co